Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Effect of Protein on Calcium Absorption and Gastric Acid Production
This study has been completed.
Sponsored by: Yale University
Information provided by: Yale University
ClinicalTrials.gov Identifier: NCT00719160
  Purpose

We have established that dietary protein is an important regulator of intestinal calcium absorption in humans. However, we do not understand the mechanism by which dietary protein is affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether dietary protein-induced changes in gastric acid secretion explain the observed changes in intestinal calcium absorption.


Condition Intervention Phase
Osteoporosis
Drug: esomeprazole
Phase IV

MedlinePlus related topics: Calcium Dietary Proteins Osteoporosis
Drug Information available for: Calcium gluconate Esomeprazole magnesium Esomeprazole Sodium Omeprazole Omeprazole magnesium
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Official Title: Dietary Protein's Effect on Gastric pH and Calcium Absorption

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Intestinal calcium absorption [ Time Frame: Day 5 of a high protein diet ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Gastric pH [ Time Frame: Day 5 of a high protein diet ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: January 2005
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: esomeprazole
    2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
Detailed Description:

We have established that dietary protein is an important regulator of intestinal calcium absorption in humans. However, we do not understand the mechanism by which dietary protein is affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether dietary protein-induced changes in gastric acid secretion explain the observed changes in intestinal calcium absorption. We have compelling in vitro data that amino acids can stimulate gastric acid secretion. We have found that this occurs via allosteric activation of the calcium sensing receptor expressed on the gastric acid-secreting parietal cells. At a fixed concentration of extracellular calcium, addition of L but not D isomers of specific amino acids activates the calcium sensing receptor and stimulates parietal cell acid production. We hypothesize that dietary protein induced gastric acid production increases calcium solubility and bioavailability thereby increasing its absorption. We will test this hypothesis in humans by quantifying the impact of dietary protein on intestinal calcium absorption in subjects who cannot make gastric acid. We will measure intestinal calcium absorption in healthy adults as they consume either a high protein diet with concomitant administration of a proton pump inhibiting drug or the same high protein diet with a placebo instead of a PPI. The order of the 2 interventions will be randomized, and study will be double-blind and placebo controlled. If our hypothesis is correct, then intestinal calcium absorption will be highest during the high protein diet with placebo, and lowest during the drug intervention.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men and women age 18-45 years
  • Caucasian or Asian descent due to increased risk of Osteoporosis

Exclusion Criteria:

  • gastrointestinal diseases
  • osteoporosis
  • diabetes
  • hypertension
  • liver disease
  • thyroid disorders
  • kidney disease
  • kidney stones
  • cancer
  • heart disease
  • eating disorders
  • obesity
  • hypogonadism
  • amenorrhea
  • oligomenorrhea
  • abnormal serum FSH or estradiol levels
  • birth control medication or other hormone-altering medications
  • pregnancy
  • Lifestyle factors such as:

    • smoking
    • excessive exercise (although moderate exercise is allowed)
    • prescription medications known to influence vitamin D or calcium metabolism or gastric acid
    • excessive body weight change during the past 6 months
    • food allergies
    • unusual eating habits or medically prescribed diets
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00719160

Locations
United States, Connecticut
Yale New Haven Hospital Hospital Research Unit
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Karl Insogna, MD Yale University
  More Information

Responsible Party: Yale University School of Medicine ( Karl Insogna, MD )
Study ID Numbers: 0408026977
Study First Received: July 17, 2008
Last Updated: December 22, 2008
ClinicalTrials.gov Identifier: NCT00719160  
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
Gastric acid
Dietary protein
Calcium
Intestinal absorption
Calcium sensing receptor

Study placed in the following topic categories:
Calcium, Dietary
Musculoskeletal Diseases
Omeprazole
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009